MEK inhibitors in non-V600 BRAF mutations and fusions

Mutations in BRAF at the 600th codon have proven sensitive to combination BRAF and MEK inhibition. Mutations outside this codon, however, are approximately as common but do not have approved targeted therapy approaches. Herein, we discuss targeting these non-V600 mutation and fusions in BRAF with ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Douglas B., Nebhan, Caroline A., Noel, Marcus S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Research Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646828/
https://www.ncbi.nlm.nih.gov/pubmed/33216832
http://dx.doi.org/10.18632/oncotarget.27788
_version_ 1783606855990247424
author Johnson, Douglas B.
Nebhan, Caroline A.
Noel, Marcus S.
author_facet Johnson, Douglas B.
Nebhan, Caroline A.
Noel, Marcus S.
author_sort Johnson, Douglas B.
collection PubMed
description Mutations in BRAF at the 600th codon have proven sensitive to combination BRAF and MEK inhibition. Mutations outside this codon, however, are approximately as common but do not have approved targeted therapy approaches. Herein, we discuss targeting these non-V600 mutation and fusions in BRAF with MEK inhibitors.
format Online
Article
Text
id pubmed-7646828
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-76468282020-11-17 MEK inhibitors in non-V600 BRAF mutations and fusions Johnson, Douglas B. Nebhan, Caroline A. Noel, Marcus S. Oncotarget Research Perspective Mutations in BRAF at the 600th codon have proven sensitive to combination BRAF and MEK inhibition. Mutations outside this codon, however, are approximately as common but do not have approved targeted therapy approaches. Herein, we discuss targeting these non-V600 mutation and fusions in BRAF with MEK inhibitors. Impact Journals LLC 2020-11-03 /pmc/articles/PMC7646828/ /pubmed/33216832 http://dx.doi.org/10.18632/oncotarget.27788 Text en Copyright: © 2020 Johnson et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Perspective
Johnson, Douglas B.
Nebhan, Caroline A.
Noel, Marcus S.
MEK inhibitors in non-V600 BRAF mutations and fusions
title MEK inhibitors in non-V600 BRAF mutations and fusions
title_full MEK inhibitors in non-V600 BRAF mutations and fusions
title_fullStr MEK inhibitors in non-V600 BRAF mutations and fusions
title_full_unstemmed MEK inhibitors in non-V600 BRAF mutations and fusions
title_short MEK inhibitors in non-V600 BRAF mutations and fusions
title_sort mek inhibitors in non-v600 braf mutations and fusions
topic Research Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646828/
https://www.ncbi.nlm.nih.gov/pubmed/33216832
http://dx.doi.org/10.18632/oncotarget.27788
work_keys_str_mv AT johnsondouglasb mekinhibitorsinnonv600brafmutationsandfusions
AT nebhancarolinea mekinhibitorsinnonv600brafmutationsandfusions
AT noelmarcuss mekinhibitorsinnonv600brafmutationsandfusions

Ejemplares similares